Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antrocaryon micraster seed aqueous fraction (ASEA) is a natural plant extract derived from the seeds of the tropical rainforest tree *Antrocaryon micraster* (Anacardiaceae). It is primarily studied for its antiarthritic and antioxidant properties. ASEA is obtained by partitioning a 70% ethanol Soxhlet seed extract into an aqueous phase, resulting in a fraction rich in polyphenolic constituents and phytosterols. In preclinical models of rheumatoid arthritis, such as Complete Freund's Adjuvant (CFA)-induced arthritis in rats, ASEA has demonstrated significant activity by inhibiting protein denaturation, oxidative stress, inflammatory cell infiltration, and synovium injury. Its in vitro antiarthritic potency has been reported to be significantly higher than that of diclofenac sodium.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on antrocaryon micraster seed aqueous fraction.